Holen Sie sich die Stockscreener-App
0.7753
10.76%
0.0753
Handel nachbörslich:
.78
0.0047
+0.61%
Schlusskurs vom Vortag:
$0.70
Offen:
$0.695
24-Stunden-Volumen:
5.03M
Relative Volume:
0.77
Marktkapitalisierung:
$48.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-0.9814
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
+36.50%
1M Leistung:
+204.04%
6M Leistung:
+0.78%
1J Leistung:
-58.76%
1-Tages-Spanne:
$0.681
$0.785
1-Wochen-Bereich:
$0.5919
$0.785
52-Wochen-Spanne:
$0.2223
$2.535
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Vergleichen Sie CGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7753 | 35.21M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
What drives Cognition Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com
Is Cognition Therapeutics Inc. a good long term investmentUnbelievable profit margins - jammulinksnews.com
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
Cognition Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
What analysts say about Cognition Therapeutics Inc. stockExceptional ROI - jammulinksnews.com
How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru
Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Cognition Therapeutics stock soars after DLB study results - Investing.com
Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com South Africa
CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire
Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser
Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest
CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World
Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance
Cognition Therapeutics, Inc. (CGTX) Plunges 14.29% Amid FDA Meeting Outcome - AInvest
Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest
Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Inc. (CGTX) Soars 31.45% on FDA Phase 3 Trial Approval - AInvest
Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug - Investing.com Nigeria
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine - Seeking Alpha
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug - Investing.com
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Conducts Meeting With US FDA to Review Phase 2 Study Results of Zervimesine - MarketScreener
Cognition Therapeutics Soars 61.65% on Positive FDA Meeting - AInvest
Cognition Therapeutics: Zervimesine Emerges as Alzheimer's Breakthrough with FDA Backing and NIH Support - AInvest
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):